Search | IOVS | ARVO Journals

Showing 1 – 19 of 19

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

Beyond GWAS: Functional genomics of age-related macular degeneration

Anand Swaroop; Freekje Van Asten; Madeline Kwiklis; Kayode Sosina; Margaret Starostik; Nivedita Singh; Dena Hernandez; Emily Y Chew; Andrew Singleton; Alexis Battle; Deb A Ferrington; Nilanjan Chatterjee; Rinki Ratnapriya

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4246. doi:

ARVO Annual Meeting Abstract July 2018

Epigenetic disease mechanisms associated with age-related macular degeneration

Freekje Van Asten; Ximena Corso Diaz; Vijender Chaitankar; Rinki Ratnapriya; Margaret Starostik; Emily Y. Chew; Deborah A. Ferrington; Anand Swaroop

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):370. doi:

ARVO Annual Meeting Abstract July 2018

Epigenomic reconfiguration during aging of rod photoreceptors

Ximena Corso Diaz; Ryan Rebernick; Catherine Jaeger; Freekje Van Asten; Matthew Brooks; Tiziana Cogliati; Vijender Chaitankar; Anand Swaroop

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3490. doi:

ARVO Annual Meeting Abstract July 2018

Geographic atrophy of age-related macular degeneration in the Age-Related Eye Disease Study 2 (AREDS2): incidence, clinical characteristics and factors influencing growth rate

Tiarnan D L Keenan; Elvira Agron; Amitha Domalpally; Traci E Clemons; Freekje Van Asten; Wai T Wong; Ronald P Danis; Michael L Klein; Rinki Ratnapriya; Anand Swaroop; Frederick L Ferris; Emily Y. Chew

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6010. doi:

ARVO Annual Meeting Abstract July 2018

Association of Diet to the Development of Late AMD in Participants of AREDS

Elvira Agron; Emily Y. Chew; Julie A. Mares; Esther MEZHIBOVSKY; Traci E Clemons; Freekje Van Asten

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2381. doi:

ARVO Annual Meeting Abstract June 2017

Deep Phenotype Association Study in AREDS2 Suggests Pleiotropic Genetic Associations with Ocular and Systemic Disease

Tiarnan D Keenan; Michael Simmons; Freekje Van Asten; Ayush Singhal; Rinki Ratnapriya; Elvira Agron; Anand Swaroop; Zhiyong Lu; Emily Chew

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):177. doi:

ARVO Annual Meeting Abstract June 2017

A Deep Phenotype Association Study (DeePAS) in AREDS2 reveals specific phenotype associations with AMD-related genetic variants

Freekje Van Asten; Michael Simmons; Ayush Singhal; Rinki Ratnapriya; Elvira Agron; Anand Swaroop; Zhiyong Lu; Emily Chew

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2984. doi:

ARVO Annual Meeting Abstract June 2017

Effect of Nutrient Intake in Genetically at-Risk Participants on the Development of AMD in AREDS

Elvira Agron; Emily Chew; Traci E Clemons; Freekje Van Asten

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3207. doi:

ARVO Annual Meeting Abstract June 2017

Genetic Interaction with Response to Oral Micronutrient Supplements in the Age-Related Eye Disease Study 2 (AREDS2)

Emily Chew; Chi-Yang Chiu; Elvira Agron; Traci E Clemons; Freekje van Asten; Ruzong Fan

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2985. doi:

ARVO Annual Meeting Abstract June 2017

Rare Variant Pathway Analysis in the Age-Related Eye Disease Study 2

Alexandra Pietraszkiewicz; Freekje Van Asten; Alan Kwong; Rinki Ratnapriya; Goncalo Abecasis; Anand Swaroop; Emily Chew

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1833. doi:

ARVO Annual Meeting Abstract June 2017

Transcriptional and DNA methylation changes during aging in rod photoreceptors

Ximena Corso Diaz; Freekje Van Asten; Tiziana Cogliati; Jennifer Joanna Barb; Norimoto Gotoh; Matthew Brooks; Anand Swaroop

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1844. doi:

ARVO Annual Meeting Abstract June 2017

Hyperreflective foci predict treatment response to bevacizumab in patients with diabetic macular edema

Vivian Schreur; Lebriz Altay; Freekje Van Asten; Joannes Groenewoud; Jeroen Klevering; Carel C B Hoyng; Eiko de Jong

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1896. doi:

Retina April 2017

Automated Staging of Age-Related Macular Degeneration Using Optical Coherence Tomography

PDF

Freerk G. Venhuizen; Bram van Ginneken; Freekje van Asten; Mark J. J. P. van Grinsven; Sascha Fauser; Carel B. Hoyng; Thomas Theelen; Clara I. Sánchez
TAGS: age-related macular degeneration, machine learning, optical coherence tomography, datasets, volume
Invest. Ophthalmol. Vis. Sci.. 2017; 58(4):2318-2328. doi: https://doi.org/10.1167/iovs.16-20541

ARVO Annual Meeting Abstract September 2016

Risk Factors for Diabetic Retinopathy in Type 1 Diabetes Mellitus Patients with Poor Glycemic Control

Vivian Schreur; Freekje Van Asten; Heijan Ng; Jack Weeda; Cees Tack; Carel C B Hoyng; B. Jeroen Klevering; Eiko de Jong

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1598. doi:

ARVO Annual Meeting Abstract September 2016

No excuses. Bevacizumab should be first choice in AMD.

Freekje Van Asten; Charlotte Michels; Carel C B Hoyng; Gert Jan van der Wilt; B. Jeroen Klevering; Maroeska M. Rovers; Janneke P.C. Grutters

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3331. doi:

ARVO Annual Meeting Abstract June 2015

A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration

Laura Lorés de Motta; Freekje Van Asten; Philipp S Muether; Dzenita Smailhodzic; John C Chen; Robert K Koenekoop; Sascha Fauser; Carel C B Hoyng; Anneke I Den Hollander; Eiko de Jong

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3990. doi:

ARVO Annual Meeting Abstract June 2015

Adalimumab Therapy for Refractory Birdshot Chorioretinopathy

Freekje Van Asten; Paulien HuisinhetVeld; Robert W.A.M. Kuijpers; Aniki Rothova; Eiko de Jong; Carel C B Hoyng

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3119. doi:

ARVO Annual Meeting Abstract April 2014

Are intravitreal injections with ultrathin 33G needles less painful?

Freekje van Asten; Henriët van Middendorp; Samuël Verkerk; Myrte Breukink; Carel C B Hoyng; Andrea W Evers; B Jeroen Klevering

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):581. doi:

ARVO Annual Meeting Abstract June 2013

Predicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration

Freekje van Asten; Maroeska Rovers; Yara Lechanteur; Dzenita Smailhodzic; Philipp Muether; Anneke Den Hollander; Sascha Fauser; Carel Hoyng; Gert Jan van der Wilt; B. Jeroen Klevering

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):246. doi:

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Beyond GWAS: Functional genomics of age-related macular degeneration

Epigenetic disease mechanisms associated with age-related macular degeneration

Epigenomic reconfiguration during aging of rod photoreceptors

Geographic atrophy of age-related macular degeneration in the Age-Related Eye Disease Study 2 (AREDS2): incidence, clinical characteristics and factors influencing growth rate

Association of Diet to the Development of Late AMD in Participants of AREDS

Deep Phenotype Association Study in AREDS2 Suggests Pleiotropic Genetic Associations with Ocular and Systemic Disease

A Deep Phenotype Association Study (DeePAS) in AREDS2 reveals specific phenotype associations with AMD-related genetic variants

Effect of Nutrient Intake in Genetically at-Risk Participants on the Development of AMD in AREDS

Genetic Interaction with Response to Oral Micronutrient Supplements in the Age-Related Eye Disease Study 2 (AREDS2)

Rare Variant Pathway Analysis in the Age-Related Eye Disease Study 2

Transcriptional and DNA methylation changes during aging in rod photoreceptors

Hyperreflective foci predict treatment response to bevacizumab in patients with diabetic macular edema

Automated Staging of Age-Related Macular Degeneration Using Optical Coherence Tomography

Risk Factors for Diabetic Retinopathy in Type 1 Diabetes Mellitus Patients with Poor Glycemic Control

No excuses. Bevacizumab should be first choice in AMD.

A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration

Adalimumab Therapy for Refractory Birdshot Chorioretinopathy

Are intravitreal injections with ultrathin 33G needles less painful?

Predicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration

To View More...

You must be signed into an individual account to use this feature.